Status:
RECRUITING
Reduced-dose Alemtuzumab for Kidney Transplant Rejection
Lead Sponsor:
Erasmus Medical Center
Conditions:
Kidney Transplant Rejection
Eligibility:
All Genders
18+ years
Brief Summary
Prospective, follow-up study of kidney transplant recipients treated with alemtuzumab anti-rejection therapy for severe or glucocorticoid-resistant kidney transplant rejection.
Detailed Description
Study design: Prospective observational cohort study. Study population: Adult patients who are treated with alemtuzumab for severe or glucocorticoid-resistant kidney transplant rejection. Interventio...
Eligibility Criteria
Inclusion
- 18 years or older
- Treatment for severe or glucocorticoid-resistant kidney transplant rejection with alemtuzumab.
Exclusion
- Treatment with a different lymphocyte depleting agent (e.g. rATG) prior to treatment with alemtuzumab for the same rejection episode.
- Recipients who have T cell counts below 200 × 106/L before the start of therapy (for instance, because of lymphocyte depleting induction therapies).
- Inability to provide written informed consent
Key Trial Info
Start Date :
December 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06100965
Start Date
December 1 2023
End Date
July 1 2026
Last Update
February 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015 GD